In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET negativity, but, as Dr. Fornecker reported, increased toxicity.
Skip Nav Destination
Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin Lymphoma
December 30, 2021
Content License:Private